Finds predictors of treatment response in basal cell carcinoma, indicating potential for improved outcomes with BO-112.
Background: Basal cell carcinoma (BCC) represents about 75% of all keratinocyte cancers with a 30% average lifetime risk for white-skinned individuals to develop BCC [1]. Micrographically Controlled Surgery is a recommended treatment option for BCC in cosmetically sensitive areas of head and neck, whereas non-surgical treatment alternatives are mostly reserved for superficial and nodular BCC on the body and extremities. BO-112, a novel immune-oncology intralesional treatment, may provide a new treatment option for BCC patients.
No takes yet. Share an insight, caveat, or question.
Cañueto et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: